CoChat

Advanced Glycation End Products, Measured as Skin Autofluorescence and Diabetes Complications: A Systematic Review

Bos, Dieuwke C., de Ranitz-Greven, Wendela L., de Valk, Harold W. · 2011 · Diabetes Technology & Therapeutics
Cited by 93

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Advanced glycation end products (AGEs) are long-lived tissue proteins that accumulate in diabetes. Skin AGEs measured in biopsy specimens strongly correlated with complications of diabetes. AGEs can also be measured noninvasively by the AGE Reader™ (DiagnOptics B.V., Groningen, The Netherlands). The aim of this review was to systematically review all articles on the association between skin autofluorescence (SAF), measured by the AGE Reader, and complications of diabetes. METHODS: We screened PubMed for studies on SAF and complications in diabetes mellitus type 1 and type 2. Seven articles met the inclusion criteria. RESULTS: All studies showed positive associations of SAF with one or more complications (all-cause mortality, cardiovascular mortality, micro- and macrovascular complications, neuropathy, and nephropathy), except retinopathy. Only three studies were of prospective design, with a follow-up of 3-5 years; the other four studies were cross-sectional. Studies were of large clinical heterogeneity. CONCLUSIONS: This systematic review of literature showed an association of SAF with end-organ complications in diabetes, except retinopathy, in all seven studies. However, studies were of large clinical heterogeneity, only three studies had a prospective design, and five studies were from the same research group. More prospective studies, with a longer period of follow-up, larger group size, and strict definitions of complications and end points, are needed to demonstrate the potential role and benefit in clinical management before the widespread use of the AGE Reader can be recommended.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2011.0034

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 93

Metadata

Authors
Bos, D. C., de Ranitz-Greven, W. L., & de Valk, H. W.
Venue
Diabetes Technology & Therapeutics
Published
2011-07
Volume
13
Issue
7
Pages
773-779
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2081901990
Cited by
93
References
3
FWCI
0.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advanced Glycation End Products, Measured as Skin Autofluorescence and Diabetes Complications: A Systematic Review. https://app.cochat.ai/papers/10.1089/dia.2011.0034
The paper
Bos, D. C., de Ranitz-Greven, W. L., & de Valk, H. W. (2011). Advanced Glycation End Products, Measured as Skin Autofluorescence and Diabetes Complications: A Systematic Review. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2011.0034

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.